MATR3 and nonpapillary renal cell carcinoma: Based on the TCGA dataset sourced from the Xena database, two-marker combinations yielded the best separation of the ccRCC patients according to their survival, with a p-value of p < 0.0001 and patients in MATR3-high/MRPL23-low group not reaching the median OS, and those in the opposite group experiencing the worst survival (1111 days; Figure S6).